Loading
Actinium-225 can be made in particle accelerators, but the product contains a trace of a long-lived impurity that regulators have not agreed how to handle. Settle the limit and build the hubs.
Proton irradiation of radium-226 yields actinium-225 with a small admixture of actinium-227 (half-life 21.8 years), while electron linac photonuclear and high-energy spallation routes differ in impurity profile. Without a harmonised monograph, each producer negotiates specifications with each regulator, slowing investment. The proposal is a joint European, US and Japanese pharmacopoeia monograph setting actinium-227 and other radionuclidic impurity limits based on dosimetry and waste handling, paired with public co-investment in three to five regional cyclotron or linac hubs sized for clinical supply.
Shares Alpha vs beta emitters, Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Targeted alpha therapy, Manufacturing cost and time for living and radioactive medicines.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Targeted alpha therapy, Manufacturing cost and time for living and radioactive medicines.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Regulatory divergence between regions, Manufacturing cost and time for living and radioactive medicines.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Regulatory divergence between regions, Manufacturing cost and time for living and radioactive medicines.
Shares Alpha vs beta emitters, Dosimetry, Targeted alpha therapy.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines.